Innovent Biologics Inc
Company Profile
Business description
Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has eight commercialized oncology products and two commercialized non-oncology products as of August 2023. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.
Contact
168 Dongping Street
Suzhou Industrial Park, Jiangsu
Suzhou215123
CHNT: +86 51269566088
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
5,263
Innovent Biologics Inc News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,520.10 | 48.60 | 0.57% |
| CAC 40 | 7,316.92 | 34.23 | 0.47% |
| DAX 40 | 19,921.27 | 72.50 | 0.37% |
| Dow JONES (US) | 43,325.80 | 28.77 | 0.07% |
| FTSE 100 | 8,123.00 | 13.99 | -0.17% |
| HKSE | 20,090.46 | 7.83 | -0.04% |
| NASDAQ | 20,020.36 | 10.77 | -0.05% |
| Nikkei 225 | 40,281.16 | 713.10 | 1.80% |
| NZX 50 Index | 13,205.10 | 130.36 | 1.00% |
| S&P 500 | 6,037.59 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,261.80 | 40.90 | 0.50% |
| SSE Composite Index | 3,400.14 | 2.07 | 0.06% |